OAKLAND, Calif.--Joel Bellenson, a cofounder of Pangea Systems here, will serve as director of the company's Scientific Advisory Board and its chief strategist. As reported in the previous issue of BioInform, Bellenson was succeeded last month as Pangea's CEO by former Apple executive John Couch. Pangea is a leading bioinformatics software company.
Commenting on the new CEO, Bellenson noted that Couch's "strategic guidance and leadership will be essential as we expand our bioinformatics platform and product line and develop new applications to simplify and accelerate drug discovery." Couch remarked, "We have the opportunity to define a new market that will deliver the essential software platform for translating raw data into information for drug discovery. Right now, the need for high-throughput informatics tools for genome analysis is greater in scope than any single company can provide. Pangea has already developed and in-licensed many of the best bioinformatics algorithms and methods for deriving high-value, computationally processed information from genomic data, and has productive scientific research programs in these areas."
"What really sets Pangea apart is that we're offering these solutions in the context of an open platform standard for drug discovery informatics that anyone can add value to," he added. "This is an inclusive, rather than a proprietary approach that enables the formation of complete solutions based on industrial-strength database architecture and the best algorithms available. With our open approach, we can extend our partnership with the customer throughout their entire drug development process, giving them the benefits of enterprise-wide data management, secure access, and the best analysis tools for their work all along the way."